SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MultiCell Technologies, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: EACarl who wrote (70)8/10/2005 8:10:55 AM
From: Tradenride  Respond to of 237
 
Agreeing to just a 1 for 5 instead of a 1 for 10 was the boards first huge mistake. It was like, OK Tony, whatever you say! They could have done a 1 for 10, been eligible for Amex and left Tony out of it not paying him a dime. Now, because Amex is not going to let Tony bring another bankrupt company aboard, the pivotal 1.00 is being threatened and the rest will be history. Proven history of 95% of OTCBB's that do a RS for the purpose of more financing.



To: EACarl who wrote (70)8/21/2005 8:54:51 AM
From: Tradenride  Respond to of 237
 
eac756, did you see what happened to Cambrex stock after the announcement of acquiring the immortalized cell lines Fa2n-4 and EA1C-35. The street was not very happy. Not happy at all. It took an initial hit of $2 that day followed by a 33% loss of value descending to $18 close to where it currently trades today. Shouldn't this be a wake up call for Multicell!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News